Merck Names Sanat Chattopadhyay President of Merck Manufacturing Division; Will Succeed Willie A. Deese Who Will Retire


March 7, 2016 4:30 pm ET

Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the appointment of Sanat Chattopadhyay as executive vice
president and president, Merck Manufacturing Division (MMD), effective
April 1, 2016. Chattopadhyay will succeed Willie A. Deese who will
retire on June 1, 2016 after 12 years with the company.

“With more than 30 years of biopharmaceutical industry experience, Sanat
has a proven track record of commercialization, manufacturing and supply
chain excellence in therapeutic proteins, vaccines and pharmaceuticals.
Under his leadership I am confident that MMD will continue to advance
toward its goal of becoming a world-class supplier,” said Kenneth C.
Frazier, chairman and chief executive officer, Merck.

Chattopadhyay joined Merck in 2009 and currently serves as senior vice
president of Global Manufacturing Operations (Human Health). He was
instrumental in transforming Merck Vaccines’ manufacturing and supply to
grow and globalize the company’s vaccines business. Chattopadhyay also
played a key part in leading the company’s launch of KEYTRUDA
(pembrolizumab) in record time by mobilizing a cross-divisional effort
to overcome commercialization and supply constraints.

Deese joined Merck in 2004 to lead the global procurement team in MMD.
In 2005, he was promoted to president of MMD and joined the company’s
executive committee. Among his many accomplishments as president of MMD
was the “Target ’15” strategy, a five-year program that improved both
operational efficiencies in manufacturing and financial results.
Additionally, Deese led the company’s multi-year, strategic initiative
to sharpen its commercial and research and development focus, redesign
its operating model and reduce its cost base. The initiative succeeded
in exceeding its goal by the end of 2015 of realizing $2.5 billion in
annual net cost savings versus 2012.

“Under Willie’s leadership, we significantly improved our ability to
serve patients and customers globally and transformed our operating
model,” said Frazier. “I would like to thank Willie for his unwavering
focus on high performance, safety, compliance, and above all, customers
and patients.”

About Merck

Today’s Merck is a global health care leader working to help the world
be well. Merck is known as MSD outside the United States and Canada.
Through our prescription medicines, vaccines, biologic therapies and
animal health products, we work with customers and operate in more than
140 countries to deliver innovative health solutions. We also
demonstrate our commitment to increasing access to health care through
far-reaching policies, programs and partnerships. For more information,
and connect with us on Twitter,
and LinkedIn.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the
“company”) includes “forward-looking statements” within the meaning of
the safe harbor provisions of the U.S. Private Securities Litigation
Reform Act of 1995. These statements are based upon the current beliefs
and expectations of the company’s management and are subject to
significant risks and uncertainties. If underlying assumptions prove
inaccurate or risks or uncertainties materialize, actual results may
differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest
rate and currency exchange rate fluctuations; the impact of
pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care cost
containment; technological advances, new products and patents attained
by competitors; challenges inherent in new product development,
including obtaining regulatory approval; the company’s ability to
accurately predict future market conditions; manufacturing difficulties
or delays; financial instability of international economies and
sovereign risk; dependence on the effectiveness of the company’s patents
and other protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause results
to differ materially from those described in the forward-looking
statements can be found in the company’s 2015 Annual Report on Form 10-K
and the company’s other filings with the Securities and Exchange
Commission (SEC) available at the SEC’s Internet site (

Lainie Keller, 908-236-5036
Claire Gillespie, 267-305-0932
Teri Loxam, 908-740-1986
Justin Holko, 908-740-1879

Unsubscribe from email alerts